Teva: Amgen’s Interchangeable Humira Biosimilar Too Late For January 2023

Israeli Firm Commits To Debt Repayment And Rules Out High-Cash Deals

 
• By Dean Rudge
  
launch
Teva has weighed in on rival Amgen's biosimilar Humira candidate • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products